JPRN-UMIN000034963已完成未知
A randomized, double-blind, placebo-controlled parallel-group superiority study on the skin function index of ingredient obtained from plant in healthy adult females - A randomized, double-blind, placebo-controlled parallel-group superiority study on the skin function index of ingredient obtained from plant in healthy adult females
KT Medical Corporation0 个研究点目标入组 120 人开始时间: 2018年11月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 55years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Individuals who use regularly cosmetology or food affecting the skin condition 2) Individuals who have skin disease, or whose skin have an abnormality requiring treatment, or who have disease with affecting skin condition 3) Individuals who need to wear masks or to blow their nose due to allergic rhinitis or individuals who maybe develop the allergy during the study 4) Individuals who have chronic disease 5) Individuals with serious disorders or individuals with histories of serious disorders 6) Individuals who excessively take alcohol 7) Individuals who is smoker (smoking over 20 cigarettes/day) 8) Individuals who have a history of serious drug allergy or serious food allergy 9) Individuals who are pregnant or Individuals who are willing to become pregnant or lactation during this study 10) Individuals who are participating in other clinical trials or individuals who participated in other clinical trials within 1 month 11) Any Individuals considered to be unsuitable for enrollment in the opinion of the principal investigator
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-weektreatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers - SURSMOKEAid to smoking cessation in cigarette smokersMedDRA version: 8.1Level: LLTClassification code 10057852Term: Nicotine dependenceEUCTR2006-005334-21-BEsanofi-aventis recherche et developpement805
进行中（未招募）
不适用
The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptyingInvestigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.MedDRA version: 16.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-004438-32-DEGlaxoSmithKline Research and Development Limited70
进行中（未招募）
1 期
A study to evaluate the efficacy of AFQ056 in treating abnormal behaviors showed by adolescents (12-17 year-old) with Fragile X SyndromeFragile X SyndromeMedDRA version: 13.1Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-022638-96-FRovartis Pharma Services AG180
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptomsEUCTR2005-003788-22-GBBoehringer Ingelheim Limited318
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel-group, multi-centre, Phase IIb, study to determine the effect of BXL628 in women with detrusor overactivity - BXL628 effect in OABOveractive Bladder (OAB)MedDRA version: 9.1Level: LLTClassification code 10020853Term: Hypertonic bladderEUCTR2007-001214-16-ITBIOXELL SPA234